HighTide Therapeutics

Join HighTide at the H.C. Wainwright 26th Annual Global Investment Conference Sept. 9-11, to hear the latest from Chief Development Officer Leigh MacConell about our development of multifunctional, multi-targeted therapies for chronic liver & metabolic diseases. The company will also be participating in investor meetings. 📺 Register to watch the webcast (starting 7am EDT on Sept. 9 and available for 90 days): https://lnkd.in/eU_MevYx #metabolicdisease #liverdisease #pharma #drugdevelopment #HCWainwright

ENROLLMENT COMPLETE: Our two Phase III clinical trials testing berberine ursodeoxycholate (HTD1801) in patients with type 2 #diabetes have completed enrollment. Both trials are evaluating our first-in-class gut-liver anti-inflammatory metabolic modulator for its effects on HbA1c and other indicators of glucose metabolism, lipids, markers of liver injury/function, and inflammation in patients with #T2DM; the first (SYMPHONY-1/NCT06350890) in patients who have poor glycemic control after dietary and exercise interventions, and the second (SYMPHONY-2/NCT06353347) in patients whose diabetes is inadequately controlled with metformin. Thank you to our team and all participants in these important studies. https://ow.ly/VlBV50SoYQ7 $2511HK #metabolicdisorders #pharma #clinicaltrials #drugdevelopment

📢 NEWS FROM #ADASciSessions: 12 weeks of treatment with our gut-liver anti-inflammatory metabolic modulator berberine ursodeoxcycholate (HTD1801) led to significant improvements in glycemic and cardiometabolic health in Type 2 #diabetes patients, regardless of baseline disease severity. As presented today at the American Diabetes Association 84th Scientific Sessions, the post-hoc analysis evaluated the effectiveness of HTD1801 in patients with #T2DM across the disease spectrum based on baseline HbA1c, with a particular emphasis on glycemic and lipid metabolism markers, along with indicators of liver injury. Based on the successful Phase 2 study, two Phase 3 studies (NCT06350890, NCT06353347) are currently ongoing to further evaluate the efficacy and safety of HTD1801 (as monotherapy and as add-on to metformin) in patients with T2DM and inadequate control. 📚 Learn more about the Phase 2 study analysis: https://ow.ly/mVSa50Sna0U 🔎 Visit our active trials: https://ow.ly/FFFP50Sna0V #HTD1801 #liverdisease #metabolicdisorders #pharma #clinicalstudies

We're excited to share the promising results of our Phase 2 study on berberine ursodeoxcycholate (HTD1801) at the #ADASciSessions! Significant improvements in glycemic and cardiometabolic health were observed in Type 2 #diabetes patients across the disease spectrum. Visit our Sunday poster session or stay tuned for details of the findings. #T2DM #HTD1801 #liverdisease #metabolicdisorders #pharma #clinicalstudies American Diabetes Association

#DYK: Your liver is your body's filter, and performs 100s of jobs to keep you healthy? Today marks Global Fatty Liver Day (formerly #NASHDay), an effort to shed light on a concealed global epidemic that will affect an estimated 357 million people by 2030. 📺 Watch this short video from Global Liver Institute: https://ow.ly/y5wC50S8yy2 📚 Get educational material in several languages and other info: https://ow.ly/jAiW50S8yy3 👩🏫 Learn more about how our gut-liver anti-inflammatory metabolic modulator, HTD1801, may provide several benefits in patients with metabolic dysfunction-associated steatohepatitis (#MASH) and #diabetes: https://ow.ly/yf9y50S8yy1 #FattyLiverDay #FattyLiver #NASH #NAFLD #liverdisease #metabolicdisorders $2511HK

A great way to pay tribute to the late, great Dr. Harrison.

🕵️♀️Could the unique mechanisms of HTD1801 make it especially well suited to patients with insulin resistance? Analysis of early trial results suggest that our lead drug candidate can improve insulin sensitivity and alleviate the metabolic inhibitory effects caused by hyperinsulinemia, leading to even greater metabolic benefits in patients with #MASH and #diabetes. Learn more at today's #EASLCongress poster session. #insulinresistance #metabolicdisorders #liverdisease #pharma $2511HK #EASL

👀 Could a gut-liver anti-inflammatory metabolic modulator provide additional benefits to #MASH & #Diabetes patients compared to the popular GLP-1 Receptor Agonists? Early trial data suggests so. Check out our #EASLCongress poster tomorrow to learn more about how our lead drug candidate, berberine ursodeoxcyholate (HTD1801), has been shown to provide greater benefit across multiple cardiometabolic endpoints compared to ongoing GLP-1RA use, including further glucose and lipid lowering, as well as weight loss. #metabolicdisorders #liverdisease #pharma $2511HK #EASL

#ICYMI: A #TBT look at #ADGHW2024 in #AbuDhabi, featuring HighTide CEO Liping Liu #pharma #liverdisease #metabolicdisorders

#BIO2024 is in full swing, and we were honored to meet up with Mr Albert Wong, Chief Executive Officer of the HKSTP - Hong Kong Science and Technology Parks Corporation. We'd love to meet you, too! Swing by our booth at the Hong Kong Pavilion, or message us to arrange a one-on-one.